 |
|
|||||||||||||||||||||||||||||||||
| [發(fā)表評論] [本類其他產(chǎn)品] [本類其他供應(yīng)商] [收藏] | ||||||||||||||||||||||||||||||||||
| 銷售商： 上海皓元生物醫(yī)藥科技有限公司 | 查看該公司所有產(chǎn)品 >> |
MCE 的所有產(chǎn)品僅用作科學(xué)研究，我們不為任何個人用途提供產(chǎn)品和服務(wù)。
Methyllycaconitine citrate
CAS No. : 351344-10-0
MCE 國際站：Methyllycaconitine citrate
產(chǎn)品活性：Methyllycaconitine citrate 是 α7 神經(jīng)元煙堿型乙酰膽堿受體 (α7nAChR) 的特異性拮抗劑。
研究領(lǐng)域：Membrane Transporter/Ion Channel | Neuronal Signaling
作用靶點：nAChR
In Vitro: Pretreatment with 5 and 10 μM Methyllycaconitine citrate (MLA) inhibits the decreased cell viability induced by Aβ25-35. Cell viability does not decrease after exposure to Methyllycaconitine citrate (2.5, 5, 10, 20 μM). Aβ25-35 treatment increases LC3-II levels, which is inhibited by administration of Methyllycaconitine citrate. Methyllycaconitine citrate also inhibits Aβ-induced autophagosome accumulation in SH-SY5Y cells. Flow cytometry also demonstrates decreased MDC-labeled vacuoles with Methyllycaconitine citrate treatment.
In Vivo: Methyllycaconitine citrate (MLA) (6 mg/kg) given alone intraperitoneally does not cause climbing behavior when compare with the saline group. Pretreatment with Methyllycaconitine citrate significantly inhibits methamphetamine (METH)-induced climbing behavior, by about 50%. Methyllycaconitine citrate does not modify either basal locomotor activity or METH-induced hyperlocomotion. The METH-induced depletion of dopamine neuron terminals is attenuated in mice pretreated with Methyllycaconitine citrate (250±43 fmol/mg, n=7). A direct effect of Methyllycaconitine citrate on body temperature is ruled out because Methyllycaconitine citrate does not affect basal body temperature (37.0±0.5°C, n=5) or reduce the METH-induced hyperthermia (38.2±0.4°C, n=6, MLA+METH group, n.s. versus METH group).
相關(guān)產(chǎn)品：Anti-Infection Compound Library | Neuronal Signaling Compound Library | Bioactive Compound Library Plus | Membrane Transporter/Ion Channel Compound Library | Carbamoylcholine chloride | PNU-282987 | GTS-21 dihydrochloride | Benzethonium chloride | Encenicline hydrochloride | Pancuronium dibromide | Sofiniclin | Anabasine | Desformylflustrabromine hydrochloride | Dinotefuran | Meclofenoxate hydrochloride | Monepantel | PNU-120596 | Tebanicline hydrochloride | Varenicline | Adiphenine hydrochloride | Hexamethonium Bromide | Lobeline hydrochloride | (+)-Sparteine | ZSET1446 | Aniracetam | Atracurium besylate | Cholesterol myristate | Decamethonium Bromide | Vecuronium bromide | A-867744 | CCMI | Cisatracurium besylate
品牌介紹:
• MCE (MedChemExpress) 擁有數(shù)百種全球獨家化合物，我們致力于為全球科研客戶提供最新最全的高品質(zhì)小分子活性化合物；
• 10,000 多種高選擇性抑制劑、激動劑涉及各熱門信號通路及疾病領(lǐng)域；
• 設(shè)有專業(yè)的實驗中心和嚴(yán)格的質(zhì)控、驗證體系；
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項質(zhì)檢報告，確保產(chǎn)品的高純度、高品質(zhì)；
• 產(chǎn)品的生物活性多經(jīng)各國客戶實驗驗證；
• Nature, Cell, Science 等多種頂級期刊及制藥專利收錄了MCE客戶的科研成果；
• 專業(yè)團隊跟蹤最新的制藥及生命科學(xué)研究進(jìn)展，為您提供全球最新的活性化合物；
• 與世界各大制藥公司及知名科研機構(gòu)建立了長期的合作。
